Last edited by JoJonos
Sunday, July 26, 2020 | History

2 edition of Economic evaluation of drug therapy for Hypercholesterolaemia in the United Kingdom found in the catalog.

Economic evaluation of drug therapy for Hypercholesterolaemia in the United Kingdom

Michael Drummond

Economic evaluation of drug therapy for Hypercholesterolaemia in the United Kingdom

by Michael Drummond

  • 348 Want to read
  • 21 Currently reading

Published by York University, Centre for Health Economics in York .
Written in English


Edition Notes

StatementMichael Drummond, Alistair McGuire, Astrid Fletcher.
SeriesHealth economics discussion paper series / York University, Centre for Health Economics -- no.104, Health economics discussion paper (York University, Centre for Health Economics) -- no.104.
ContributionsMcGuire, Alistair., Fletcher, Astrid.
ID Numbers
Open LibraryOL13973447M

Consider stopping statin therapy in patients >75 years old with physical or cognitive decline, multimorbidity, frailty, or reduced life expectancy that may limit the benefits of statin therapy. In adults aged years with an LDL-cholesterol to mmol/L ( mg/dL), consider coronary artery calcium testing to assess the need for.   In 1-way sensitivity analyses varying drug cost, analytic horizon, discount factor, magnitude of LDL-C reduction, and the proportion of statin-intolerant individuals, cost-effectiveness of PCSK9 inhibitor therapy and ezetimibe was highly sensitive only to the cost of the drug and the time horizon (with the lifetime horizon in the base analysis Cited by:

  Hypercholesterolaemia is one of the major causes of atherosclerosis. Although there are many causes, hypercholesterolaemia is the permissive factor that allows other risk factors to operate.1 The incidence of coronary heart disease is usually low where population plasma cholesterol concentrations are low.2 In Britain coronary heart disease is a major cause Cited by: The purpose of economic evaluation is to inform decisions intended to improve healthcare. The new edition of Methods for the Economic Evaluation of Health Care Programmes equips the reader with the essential hands-on experience required to undertake evaluations by providing a 'tool kit' based on the authors' own experiences of undertaking economic evaluations.

LONDON, Sept. 15, /PRNewswire/ -- INTRODUCTION Worldwide statistics indicate that there is a high cholesterol burden despite the presence of . Valvular heart disease (VHD) is frequent is industrialized countries and its prevalence increases with age due to the predominance of degenerative aetiology. Clinical approach is paramount for evaluation of the patient’s history, symptoms and for the detection of VHD by auscultation. Echocardiography plays a major role in diagnosis and assessment of severity and : Bernard Iung.


Share this book
You might also like
Indian companies with solutions that the world needs

Indian companies with solutions that the world needs

Long-term policies and programmes for youth in national development.

Long-term policies and programmes for youth in national development.

The golden sequence

The golden sequence

Alaska child labor law, and Rules and regulations.

Alaska child labor law, and Rules and regulations.

Cost-effectiveness of after-tax financing

Cost-effectiveness of after-tax financing

The Wire

The Wire

Bull Hunters Romance

Bull Hunters Romance

Metaphysics As Foundation

Metaphysics As Foundation

Guide to Writing on the Computer

Guide to Writing on the Computer

Nomination.

Nomination.

Simplicity, complexity, and modelling

Simplicity, complexity, and modelling

Poems selected from Percy Bysshe Shelley

Poems selected from Percy Bysshe Shelley

Practical language interpreted

Practical language interpreted

Even now

Even now

Economic evaluation of drug therapy for Hypercholesterolaemia in the United Kingdom by Michael Drummond Download PDF EPUB FB2

Title(s): Economic evaluation of drug therapy for hypercholesterolaemia in the United Kingdom/ M. Drummond, A.

McGuire, A. Fletcher. Country of Publication: England Publisher: York: University of York, Centre for Health Economics, Hypercholesterolemia, also called high cholesterol, is the presence of high levels of cholesterol in the blood. It is a form of hyperlipidemia, high blood lipids, and hyperlipoproteinemia (elevated levels of lipoproteins in the blood).

Elevated levels of non-HDL cholesterol and LDL in the blood may be a consequence of diet, obesity, inherited (genetic) diseases (such as LDL receptor Specialty: Cardiology.

To review the evidence for the clinical and cost-effectiveness of ezetimibe (in its licensed indication) as combination therapy or monotherapy for the treatment of primary (heterozygous familial and non-familial) hypercholesterolaemia in the by:   In this article we review published studies of the cost-effectiveness of drug therapy for hypercholesterolaemia to take stock of the principal findings that have been reported to date.

We identified 9 studies that met all criteria for inclusion in our review, including 3 of bile-acid sequestrants (cholestyramine, colestipol), 2 of an HMG-CoA reductase inhibitor (lovastatin), Cited by: 9. See the original guideline document for detailed cost-effectiveness and health economic analysis.

A costing report and costing template for implementing guidance on identification and management of familial hypercholesterolaemia (refer to "Availability of Companion Documents" field) are also provided.

To review the clinical and cost-effectiveness of ezetimibe as a combination therapy or monotherapy for the treatment of primary hypercholesterolaemia in the UK. Twelve electronic databases were. Familial hypercholesterolaemia: full guideline DRAFT (February ) Appendix E: Health economic modelling Introduction Familial hypercholesterolemia (FH) is a genetic disorder characterized by hypercholesterolemia, xanthomas, and premature coronary heart disease (CHD) Austin1 and Humphries2.

The estimated frequency of FH in western. Hypercholesterolaemia and its management Deepak Bhatnagar,1,2 Handrean Soran,1 Paul N Durrington1 Hypercholesterolaemia is one of the major causes of atherosclerosis.

Although there are many causes, hypercholesterolaemia is the permissive factor that allows other risk factors to operate.1 The incidence of File Size: KB. Childhood hypercholesterolaemia can be either primary, due to hereditary disorders such as familial hypercholesterolaemia (FH) and familial combined hyperlipidaemia (FCHL), or secondary due to obesity, diabetes mellitus or nephrotic syndrome.

Current guidelines suggest screening for hypercholesterolaemia between the ages of 2 and 10 by: We based our economic analysis on clinical data and resource consumption (drugs, drug administration, supportive care medications, disease monitoring and graded 3 or 4 adverse events) on the.

Drug uptake rate 78% - 85% Drug cost $ - $ Familial hypercholesterolaemia: full guideline DRAFT (February ) Appendix D: Health economics extractions and excluded studies Cost of a coronary event $2 - $16 Page 5 of 8.

Introduction. Familial hypercholesterolaemia (FH) is the most common and serious monogenic disorder of lipid metabolism (OMIM number: #) that leads to premature coronary heart disease (CHD).1,2 The prevalence of FH is estimated to be at least one in in the population, but in spite of major advances in scientific and clinical knowledge about the condition, most.

Therapy is a combination of lifestyle modification, nutraceuticals and drug treatment. The most convenient and effective drugs are the HMGCoA reductase inhibitors or 'statins'. They control hyperlipidaemia and help to prevent myocardial infarction, unstable Author: D.

Colquhoun. Mike Drummond & Alastair McGuire & Astrid Fletcher, "Economic evaluation of drug therapy for hypercholesterolaemia in the United Kingdom," Working Papers chedp, Centre for Health Economics, University of York.

Ágota Szende & Z. Mogyorósy & N. Muszbek & J. Nagy & G. Pallos & C Dözsa, Cited by:   This is a recording of the BMJ Best Practice Clinical Expert webinar on Hypercholesterolaemia: Current Best Practice in Evaluation & Management.

You will learn about: Evaluation of. Specialist treatment for homozygous familial hypercholesterolaemia. Drug therapy. In under 16s with homozygous FH [See page 13], LDL-C concentration may be lowered by lipid-modifying drug therapy and this should be considered before LDL apheresis.

Prescribing of drug therapy for people aged 16 and over with homozygous FH should be. Hypercholesterolaemia - familial Last revised in February Next planned review by February Back to top.

Changes. Changes. February — reviewed.A literature search was conducted in February to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials (RCTs) published since the last revision of this topic.

DRUG EVALUATION Bococizumab for the treatment of hypercholesterolaemia Nicola Ferria, Alberto Corsinib,c, Cesare R. Sirtorid and Massimiliano Ruscicab aDepartment of Pharmaceutical and Pharmacological Sciences, Università di Padova, Padoua, Italy; bDipartimento di Scienze Farmacologiche e AQ1 5 Biomolecolari, Università degli Studi di Milano, Milan, Italy.

Hypercholesterolaemia is treated with lifestyle modifications such as dietary changes, exercise, and smoking cessation, as well as pharmacological intervention with statin therapy, and selective use of the cholesterol absorption inhibitor ezetimibe or a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor.

Familial hypercholesterolaemia (FH) is a relatively common inherited cause of premature coronary artery disease. However, a significant number of people remain undiagnosed in the community.

1 Several clinical guidelines on FH have been published recently, including an Australian model of care, 1 but these need to be placed in context for general practitioners.

Evolocumab therapy could meet the threshold of $ per QALY with an annual value-based price of $ for a population with an event rate of per patient-years. This evaluation provides insights as to the economic implications of evolocumab therapy if applied to eligible patients with ASCVD in US clinical by: hypercholesterolaemia: (hī'pĕr-kŏ-les'tĕr-ol-ē'mē-ă) The presence of an abnormally large amount of cholesterol in the blood.

Synonym(s): hypercholesteremia, hypercholesterolaemia.The drug alirocumab (trade name: Praluent) has been approved since September for adults with hypercholesterolaemia or mixed dyslipidaemia whose cholesterol levels are not adequately lowered by diet and other drugs.

It can also be used if statins are not a treatment option or are not tolerated because of adverse events.